Fluticasone Nasal Spray Patient Preference Study

• Status: Completed
• Trial end date: 2006-12-04
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this study are to evaluate and compare patient preference for FF (Fluticasone Furoate) and FP (Fluticasone Propionate Aqueous)nasal sprays in the treatment of allergic rhinitis following single-dose administration.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fluticasone; Xhance

Criteria

Inclusion Criteria:

• allergic rhinitis

• literate

Exclusion Criteria:

• clinical significant uncontrolled disease

• Use of intranasal corticosteroids (<4 weeks of FP [branded or generic],<4 week exposure to FF, <4 weeks use of other INS)

• Use of intranasal medications <1 week

• Use of meds that significantly inhibit CYP4503A4

• Use of perfume or oral rinse on study day

• Allergy/intolerance to INS, antihistamines, or excipients

• Positive pregnancy test or female who is breastfeeding

• Affiliation with investigational site